PIK3CA and breast cancer: In the patients with PIK3CA-mutated BC, the ORR was 43% and 45% in the alpelisib- and placebo-treated groups, respectively, whereas in the patients with wild-type PIK3CA BC, the ORR was 63% and 61%.